Neurosense Therapeutics Ltd
NRSN1.240USD
+0.160+14.81%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
28.80MCap. mercado
PérdidaP/E TTM
Más Datos de Neurosense Therapeutics Ltd Compañía
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Información de la empresa
Símbolo de cotizaciónNRSN
Nombre de la empresaNeurosense Therapeutics Ltd
Fecha de salida a bolsaDec 09, 2021
Director ejecutivoMr. Alon Ben-Noon
Número de empleados15
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 09
Dirección11 Hamenofim St.
CiudadHERZLIYA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal4672562
Teléfono97299531142
Sitio Webhttps://www.neurosense-tx.com/
Símbolo de cotizaciónNRSN
Fecha de salida a bolsaDec 09, 2021
Director ejecutivoMr. Alon Ben-Noon
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ben-Noon (Alon)
13.24%
Rimon Gold Assets Ltd
9.60%
Gordon Ariel S
4.31%
Eisenberg (Or)
2.00%
Tracik (Ferenc)
0.79%
Other
70.05%
Accionistas
Accionistas
Proporción
Ben-Noon (Alon)
13.24%
Rimon Gold Assets Ltd
9.60%
Gordon Ariel S
4.31%
Eisenberg (Or)
2.00%
Tracik (Ferenc)
0.79%
Other
70.05%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
21.38%
Corporation
9.60%
Investment Advisor
0.29%
Research Firm
0.21%
Venture Capital
0.14%
Hedge Fund
0.11%
Investment Advisor/Hedge Fund
0.07%
Other
68.21%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
37
7.63M
31.79%
+136.65K
2025Q1
39
7.45M
37.28%
+353.50K
2024Q4
38
7.90M
34.02%
+1.29M
2024Q3
32
5.18M
22.45%
-1.31M
2024Q2
35
6.62M
30.57%
+1.57M
2024Q1
38
5.18M
33.20%
-953.28K
2023Q4
38
5.12M
32.81%
-1.05M
2023Q3
33
5.76M
47.99%
-945.27K
2023Q2
33
6.46M
53.11%
+1.06M
2023Q1
30
5.11M
43.34%
-185.85K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ben-Noon (Alon)
3.18M
13.24%
+93.67K
+3.04%
Apr 07, 2025
Rimon Gold Assets Ltd
2.30M
9.6%
+2.30M
--
Dec 02, 2024
Gordon Ariel S
1.03M
4.31%
+1.30K
+0.13%
Dec 31, 2023
Eisenberg (Or)
480.92K
2%
+20.92K
+4.55%
Apr 07, 2025
Tracik (Ferenc)
189.62K
0.79%
+66.67K
+54.22%
Apr 07, 2025
Russek-Blum (Niva)
75.43K
0.31%
+10.00K
+15.28%
Apr 07, 2025
Leuchtenberger (Mark W)
64.00K
0.27%
--
--
Apr 07, 2025
Morgan Stanley & Co. LLC
50.50K
0.21%
-52.08K
-50.77%
Mar 31, 2025
Meitav Dash Investments Ltd.
40.00K
0.17%
--
--
Mar 31, 2025
XTX Markets LLC
33.71K
0.14%
-8.19K
-19.55%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
